Home About us Editorial board Ahead of print Current issue Search Archives Submit article Instructions Subscribe Contacts Login 
ORIGINAL ARTICLE
Year : 2015  |  Volume : 11  |  Issue : 2  |  Page : 336-340

Sensitization to oxaliplatin in HCT116 and HT29 cell lines by metformin and ribavirin and differences in response to mitochondrial glutaminase inhibition


1 Laboratory of Cytogenetic and Mutagenesis, Multidisciplinary Institute of Cell Biology, Scientific Research Council, Province of Buenos Aires and National Council of Science and Technology, Argentina and Department of Science and Technology, National University of Quilmes, Buenos Aires, Argentina
2 Microscopy Laboratory Applied to Molecular and Cellular Studies, Engineering School, National University of Entre Rios, (3101) Oro Verde, Entre Rios, Argentina

Correspondence Address:
Veronica L Martinez Marignac
Microscopy Laboratory Applied to Molecular and Cellular Studies, Engineering School, National University of Entre Rios, (3101) Oro Verde, Entre Rios
Argentina
Login to access the Email id

Source of Support: None, Conflict of Interest: None


DOI: 10.4103/0973-1482.157317

Rights and Permissions

Aim of study: In the present study, we evaluated the effect of ribavirin and metformin on the sensitivity of oxaliplatin and 5-fluorouracil (5-FU) on colon cancer. Materials and Methods: Cell viability of two commercially available colon cancer cell lines (HT29 and HCT116) were analyzed by sulforhodamine B (SRB) assay. Results: A clinically achievable and nontoxic concentration of ribavirin and metformin showed a significant synergistic effect on oxaliplatin in HT29 and HCT116 cell lines. Ribavirin showed a synergistic effect on oxaliplatin in HT29 (R = 2.93, P < 0.001) and HCT116 (R = 1.71, P < 0.001), while only in HT29 metformin synergized with oxaliplatin by 2.66 (± 0.28, P < 0.01). In addition, both cell lines showed significant differences in response to Compound 968, inhibitor of mitochondrial glutaminase activity. Conclusion: The data suggested that these cell lines not only turn to metabolic different sustainability process after oxaliplatin treatment but that they also have different basal metabolic requirements of glutamine in vitro which can be exploits in the future for colorectal cancer (CRC) treatment and further studies are required.


[FULL TEXT] [PDF]*
Print this article     Email this article
 Next article
 Previous article
 Table of Contents

 Similar in PUBMED
 Related articles
 Citation Manager
 Access Statistics
 Reader Comments
 Email Alert *
 Add to My List *
 * Requires registration (Free)
 

 Article Access Statistics
    Viewed5516    
    Printed53    
    Emailed0    
    PDF Downloaded318    
    Comments [Add]    

Recommend this journal